While companies developing drugs to treat Alzheimer's disease have spent decades and many billions of dollars targeting ...

Unlike treatments that focus on removing plaques that have already formed, levetiracetam works differently. It blocks the ...

When in the clutches of β-secretase, the amyloid precursor protein (APP) lives up to its name, churning out the starting material for Aβ peptides and all that comes from them. What if this whole ...

Watching the Alzheimer’s research world from the outside over the past two years has felt like a car ride over an unpaved mountain road without a seatbelt. In 2021, the US Food and Drug Administration ...

Researchers have developed a potential new peptide-based drug delivery system by repurposing fibrils that contribute to Alzheimer’s disease pathogenesis. Researchers at the University of North ...

(A, B) ALP staining and activity detection were performed after treating cells with APPswe or BMP2 for 5 days or 7 days. (C, D) ARS staining and semiquantitative analysis were used to detect calcium ...

Beta-amyloid plaques are considered a hallmark of Alzheimer’s disease, but they’re not the sole cause of the disease and its symptoms. Alzheimer’s is a complicated disease that experts are still ...